TICKERNERD
Menu
CAICAIHealthcare · Biotechnology

CAI Stock Forecast: Caris Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$23
+13.70% on the day

The 13 Wall Street analysts covering Caris Life Sciences, Inc. hold a median 12-month price target of $27 — +16.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 8 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.4B
Ticker Nerd rank
29 / 100
Median analyst target
$27
Analysts covering
13
Total return, dividends reinvested
1W
+45.1%
1M
+30.2%
YTD
−15.7%
1Y
−20.5%
From 52W high
−42.1%
From 52W low
+56.3%
$15
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Caris Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
80
Quality
70
Revisions
66
Growth
47
Accruals
33
Size
21
Issuance
19
Volatility
17
Momentum
16

Value (80): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (16): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Caris Life Sciences, Inc. — and when they’d sell — is the membership.

Wall Street

CAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26CAIHigh $36Median $27Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
10 Buy3 Hold0 Sell
Low $21Median $27High $36

The green dot is the last close — the median target sits +16.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Aug 2026BTIGMaintainsBuy$32 → $33
6 Aug 2026Evercore ISI GroupMaintainsOutperform$25 → $26
6 July 2026Evercore ISI GroupMaintainsOutperform$30 → $25
6 July 2026Evercore ISI GroupMaintainsOutperform—
2 July 2026BTIGReiteratesBuy—
2 July 2026BTIGReiteratesBuy$32
2 June 2026Wolfe ResearchAssumesPeer Perform—
8 May 2026BTIGMaintainsBuy—
8 May 2026CitigroupMaintainsBuy—
8 May 2026JP MorganMaintainsOverweight—
13 Apr 2026JefferiesInitiatesBuy—
10 Apr 2026Piper SandlerInitiatesNeutral—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
13 Mar 2026Canaccord GenuityMaintainsHold—
27 Feb 2026BairdMaintainsOutperform—
27 Feb 2026BTIGMaintainsBuy—
27 Feb 2026Evercore ISI GroupMaintainsOutperform—
17 Feb 2026BairdInitiatesOutperform—
22 Dec 2025Canaccord GenuityMaintainsHold—
2 Dec 2025Canaccord GenuityInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−7.3%
Analysts raising
4
Analysts cutting
6
Fundamentals

Caris Life Sciences, Inc. (CAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.4×

Cheaper than 69% of US stocks

Price / sales
6.5×

Cheaper than 20% of US stocks

Price / book
10.9×

Cheaper than 10% of US stocks

EV / EBITDA
35.0×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
45.4%

Higher than 85% of US stocks

Earnings growth (YoY)
45.4%

Higher than 74% of US stocks

Gross margin
68.1%

Higher than 81% of US stocks

Operating margin
10.2%

Higher than 65% of US stocks

Net margin
10.6%

Higher than 71% of US stocks

Returns & dividend
Return on equity
20.1%

Higher than 81% of US stocks

Return on assets
8.8%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAICaris Life Sciences, Inc.$6.4B
29
SRRKScholar Rock Holding Corp.$6.4B
28
MIRMMirum Pharmaceuticals, Inc.$6.5B
71
ERASErasca, Inc.$6.3B
66
CGONCG Oncology, Inc.$6.6B
17
PTCTPTC Therapeutics, Inc.$6.1B
70
XENEXenon Pharmaceuticals, Inc.$6.0B
51
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CAI news & analysis

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Seeking Alpha · 7 Aug 2026positive

Caris Life Sciences reported another strong quarter, raising its full-year guidance and expanding margins while sustaining positive free cash flow. The company also cited accelerating clinical volume growth and the commercial launch of Caris Detect as evidence of the breadth of its growth drivers.

Why it matters — For CAI watchers, the raised guidance and continued momentum across clinical growth and the Caris Detect launch signal durability in the company's growth drivers.

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Caris Life Sciences, Inc.'s Q2 2026 earnings call. The item presents the company's earnings call coverage for the second quarter of 2026.

Why it matters — A CAI watcher would care because the earnings call transcript provides a primary source of the company's Q2 2026 results and management commentary.

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Zacks Investment Research · 5 Aug 2026positive

Caris Life Sciences, Inc. (CAI) reported break-even quarterly earnings per share for Q2, matching a loss of $0.01 per the Zacks Consensus Estimate. This compares to a loss of $0.54 per share in the same quarter a year ago.

Why it matters — A CAI watcher would track this as a meaningful improvement from the prior-year loss and a result in line with analyst expectations.

Caris Life Sciences Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Caris Life Sciences reported record clinical volume and second-quarter revenue up 45% year over year, driven by growth in molecular profiling services, higher average selling prices, and an expanding commercial organization. The company also raised its full-year revenue outlook.

Why it matters — The record clinical volume, 45% revenue growth, and raised full-year outlook signal strengthening operational momentum for CAI watchers.

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

PRNewsWire · 5 Aug 2026positive

Caris Life Sciences reported second quarter 2026 revenue of $263.7 million, up 45% year over year, driven by molecular profiling services that included about 59,200 clinical cases, over 114,000 whole exome/whole transcriptome tests, and more than 345,000 total oncology tests. The company also raised its 2026 revenue guidance to $1.03-$1.04 billion, representing 27% to 28% growth.

Why it matters — A Caris watcher would care because the company raised its full-year revenue guidance after strong quarterly growth in molecular profiling, indicating stronger-than-expected business momentum.

FAQ

Frequently asked questions about CAI stock

What is the CAI stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Caris Life Sciences, Inc. have a median 12-month price target of $27, with estimates ranging from $21 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAI stock a buy right now?

Of the 13 analysts covering Caris Life Sciences, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caris Life Sciences, Inc. 29 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAI?

As at 8 Aug 2026, Caris Life Sciences, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (80 of 100).

Will CAI stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +16.5% from the last close, and Ticker Nerd's factor model ranks Caris Life Sciences, Inc. 29 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAI stock forecast for 2030?

No analyst covering Caris Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $36 over the next 12 months.

How has CAI stock performed over the past year?

Caris Life Sciences, Inc. returned -20.5% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Caris Life Sciences, Inc. do?

Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing whole exome and whole transcriptome sequencing on patient tissue and blood samples.

What is the latest news on CAI?

The most recent item we track (Seeking Alpha, 7 Aug 2026): "Caris Life Sciences: Guidance Raised, Valuation Still Attractive". Caris Life Sciences reported another strong quarter, raising its full-year guidance and expanding margins while sustaining positive free cash flow. The company also cited accelerating clinical volume growth and the commercial launch of Caris Detect as evidence of the breadth of its growth drivers.

Company

About Caris Life Sciences, Inc.

Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing whole exome and whole transcriptome sequencing on patient tissue and blood samples. Its flagship offerings include MI Profile for tissue-based profiling, Caris Assure for blood-based analysis, and Caris Detect, a multi-cancer early detection blood assay leveraging ultra-deep whole genome sequencing. Caris has built one of the world's largest multimodal clinico-genomic databases, combining genomic, transcriptomic, and proteomic data with clinical outcomes from over 740,000 matched patient records. The company serves oncologists and patients by providing molecular information to guide therapy selection, support drug development, and enable early disease detection. Founded in 2008 and headquartered in Irving, Texas, Caris operates internationally with offices across major medical and research hubs, delivering precision medicine solutions that help physicians and patients make informed treatment decisions based on individual tumor biology.

CEO Dr. David Dean Halbert M.D. · 1,846 employees · United States · https://www.carislifesciences.com